Moderna (MRNA) Projected to Post Quarterly Earnings on Friday

Moderna (NASDAQ:MRNA) will likely be announcing its Q2 2026 results before the market opens on Friday, July 31st. Analysts expect the company to post earnings of ($2.00) per share and revenue of $102.9280 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, July 31, 2026 at 8:00 AM ET.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Friday, May 1st. The company reported ($3.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.02) by ($0.38). The firm had revenue of $389.00 million for the quarter, compared to analyst estimates of $236.37 million. Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.Moderna’s revenue for the quarter was up 260.2% on a year-over-year basis. During the same period in the prior year, the business earned ($2.52) earnings per share. On average, analysts expect Moderna to post $-6 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Moderna Stock Performance

Shares of NASDAQ MRNA opened at $55.81 on Wednesday. The company has a 50-day simple moving average of $58.87 and a 200-day simple moving average of $52.19. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.41 and a quick ratio of 2.35. The company has a market cap of $22.14 billion, a PE ratio of -6.85 and a beta of 0.94. Moderna has a 12 month low of $22.28 and a 12 month high of $85.60.

Insider Transactions at Moderna

In other news, Director Abbas Hussain sold 5,682 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $46.63, for a total value of $264,951.66. Following the transaction, the director directly owned 12,066 shares in the company, valued at $562,637.58. This trade represents a 32.01% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Noubar Afeyan sold 9,263 shares of Moderna stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $46.84, for a total value of $433,878.92. Following the completion of the transaction, the director directly owned 3,924 shares in the company, valued at $183,800.16. This represents a 70.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 125,088 shares of company stock worth $6,193,713 in the last three months. 10.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Alyeska Investment Group L.P. purchased a new stake in Moderna during the fourth quarter worth approximately $95,209,000. Invesco Ltd. raised its stake in shares of Moderna by 15.7% in the 3rd quarter. Invesco Ltd. now owns 8,216,163 shares of the company’s stock valued at $212,223,000 after acquiring an additional 1,115,131 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Moderna by 123.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,788,951 shares of the company’s stock valued at $52,775,000 after acquiring an additional 987,312 shares during the period. Worldquant Millennium Advisors LLC acquired a new position in shares of Moderna during the 2nd quarter valued at $23,192,000. Finally, Bank of America Corp DE boosted its position in Moderna by 84.3% during the 2nd quarter. Bank of America Corp DE now owns 1,779,309 shares of the company’s stock worth $49,091,000 after purchasing an additional 813,974 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Analysts Set New Price Targets

MRNA has been the topic of a number of analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Moderna in a research report on Friday, June 12th. Piper Sandler raised their price objective on Moderna from $69.00 to $77.00 and gave the stock an “overweight” rating in a report on Friday, June 26th. Bank of America lifted their price objective on Moderna from $34.00 to $38.00 and gave the company an “underperform” rating in a research report on Tuesday, July 7th. Barclays increased their target price on Moderna from $25.00 to $48.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 2nd. Finally, The Goldman Sachs Group upped their price objective on shares of Moderna from $49.00 to $67.00 and gave the company a “neutral” rating in a research note on Tuesday, July 21st. Two equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and five have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Reduce” and an average price target of $40.00.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.